In Vivo Podcasts

About In Vivo Podcasts

In Vivo Podcasts is produced by the teams behind In Vivo, Scrip and Medtech Insight and covers biopharma and medtech in one place: the strategy, the science and the deals. Every Tuesday, Strategic Intent is a candid, long-form conversation with one senior guest, including chief executives, R&D leaders, investors and regulators. Once a month, Proof of Concept goes deep on the science, from AI-designed drug discovery to the RNA therapeutics wave. And each month Scrip's Due Diligence follows the money: the M&A, licensing and financings redrawing the industry. Hosted by a rotating line-up of editors and reporters. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

Publisher

Norstella

Category

business

Language

en

Explicit

No

First episode

12 May 2026

Latest episode

13 Oct 2026

Latest episodes

26 episodes in the feed.

1. 

   13 Oct 2026

   Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown

   Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it takes to commercialize a topical dermatology drug in an increasingly scrutinized promotional environment. Commercial strategies, ad campaigns, dermatology

2. 

   6 Oct 2026

   Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’

   In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela Tanaerts, CMO and CSO at Medable, to discuss promising data from an AI Clinical Monitoring Agent.

3. 

   2 Oct 2026

   Proof of Concept - Can AI Outrun the Next Outbreak?

   What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs, joins Proof of Concept to explain how his company's AI engine maps conserved targets across 145+ pathogens to build programmable CRISPR therapeutics and rapid, lab-free diagnostics.

Contact In Vivo Podcasts

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.